Sierra F, Román E, Barreda C, Moleón M, Pastor J, Navarro A. [Effect of pamidronate infusion time on renal function in patients with multiple myeloma].
FARMACIA HOSPITALARIA 2010;
34:23-6. [PMID:
20144818 DOI:
10.1016/j.farma.2009.09.003]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2008] [Accepted: 09/09/2009] [Indexed: 10/19/2022] Open
Abstract
INTRODUCTION
Administration of biphosphonates in patients with renal failure requires a dosage adjustment.
OBJECTIVES
Analyse renal function evolution in multiple myeloma patients after reducing infusion time for 90 mg pamidronate by 2 h.
METHODS
In 2007, a retrospective study was carried out on all patients who presented multiple myeloma and bone metastasis treated with pamidronate administered every 4 h. Following a review of the literature, a protocol for administering pamidronate every 2 h was created in partnership with Haematology, and a specific dose reduction framework was established for patients with baseline renal failure. Additionally, a prospective follow-up study of those patients' renal function was completed to analyse its evolution after the change in infusion time.
RESULTS
A total of six patients received 90 mg pamidronate every 4 h. 33.32% of the patients (2/6) presented baseline renal insufficiency, and therefore needed to have the pamidronate dose adjusted according to the new protocol. Subsequently, all of them received the treatment every 2 h, and one patient (16.6%) experienced altered renal function after two treatment cycles.
DISCUSSION
Reducing administration time for pamidronate from four to 2 h did not lead to significant variations in patients' renal function. This therapeutic practice can improve patients' quality of life by shortening their hospital stay without aggravating their renal function.
Collapse